Document:

EX-10.19

 Exhibit 10.19 

EXECUTION VERSION 

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT 

THIS AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT (the “Amendment No. 1”), made and entered into this 1st day of
April, 2018 (the “Effective Date”) by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company and successor to Pharmaceutical Product Development, Inc. (the “Company”), and David S.
Simmons (the “Executive”).  
 WHEREAS, the Company and Executive are parties to that certain Employment
Agreement dated as of May 17, 2012 (the “Employment Agreement”); and  
 WHEREAS, the parties desire to
amend the Employment Agreement as set forth herein.  
 NOW, THEREFORE, that for and in consideration of the foregoing
recitals, the mutual promises, covenants and conditions contained herein, and other good and valid consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:  

1.     Capitalized Terms. Capitalized terms used in this Amendment No. 1 and not defined herein shall have the
meaning given to them in the Employment Agreement. 
 2.     Amendment. The third sentence of Section 2(b)
of the Employment Agreement be and hereby is deleted in its entirety and replaced in full by the following sentence: 
 “The Annual
Bonus shall be based on the achievement of applicable Company and individual performance metrics set forth in or established under the Company’s Senior Executive Incentive Compensation Plan, as it may be amended from time to time.” 

3.     Entire Agreement. This Amendment No. 1 constitutes the entire agreement of the parties with respect to
the subject matter hereof and supersedes all prior or contemporaneous agreements or understandings, whether written or oral, relating to the same. 

4.     Binding Effect. The Employment Agreement, as herein amended, shall continue in full force and effect. 

 IN WITNESS WHEREOF, the parties have executed this Amendment No. 1 as of the date first
above written. 
  

			
	PHARMACEUTICAL PRODUCT
	DEVELOPMENT, LLC
		
	By:	 	 /s/ B. Judd Hartman

	Name:	 	B. Judd Hartman
	Title:	 	 Chief Administrative Officer
 and General
Counsel

	
	 /s/ David S. Simmons 

	 DAVID S. SIMMONS

  

			
	Consented and agreed to by Parent:
	
	EAGLE HOLDING COMPANY I
		
	By:	 	 /s/ B. Judd Hartman

	Name:	 	B. Judd Hartman
	Title:	 	General Counsel

  
 [Signature Page to
Employment Agreement Amendment]EX-10.20

 Exhibit 10.20 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”), entered into on May 2, 2018 and effective for employment as of
May 15, 2018 (the “Effective Date”), is made by and between Pharmaceutical Product Development, LLC, a Delaware limited liability company (together with any successor thereto, the “Company”), and Christopher G.
Scully (“Executive” and, together with the Company, the “Parties”) and, solely with respect to Sections 1(c), 2(h), 9(m) and 9(n), Eagle Holding Company I, a Delaware corporation (“Parent”). Where
the context requires, references herein to the “Company” include Pharmaceutical Product Development, Inc., a North Carolina corporation and predecessor to the Company. For the avoidance of doubt, this Agreement is binding on the
Company and Executive on the date it is fully executed by both parties. 
 RECITALS 

WHEREAS, the Company previously provided Executive that certain Offer Letter, dated as of April 17, 2018 (the “Offer
Letter”); 
 WHEREAS, in conjunction with the execution of this Agreement, the Parties will enter into a Proprietary
Information and Inventions Agreement, attached hereto as Exhibit A (as amended, supplemented, or otherwise modified from time to time, the “Proprietary Information Agreement”); 

WHEREAS, the Parties desire that this Agreement replace and supersede the Offer Letter as provided herein; and 

WHEREAS, Executive and the Company mutually desire that Executive provide services to the Company on the terms herein provided. 

AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing and of the respective covenants and agreements set forth below, the Parties hereto agree as follows: 
  

	1.	 Employment. 

(a)     General. The Company shall employ Executive and Executive shall enter the employ of the Company, for the
period and in the position set forth in this Section 1, and upon and subject to the other terms and conditions herein provided. 

(b)     Employment Term. The term of employment under this Agreement (the “Term”) shall be for the
period beginning on the Effective Date and ending on December 31, 2021, subject to earlier termination as provided in Section 3. The Term shall automatically renew for additional one (1) year periods unless no later than sixty
(60) days prior to the end of the otherwise applicable Term either Party gives written notice of non-extension of the Term to the other, in which case Executive’s employment will terminate at the end
of the then applicable Term or any other date set by the Company in accordance with Section 3, subject to earlier termination as provided in Section 3. 

(c)     Position and Duties. During the Term, Executive shall serve as Executive Vice President and Chief Financial
Officer of the Company and the Parent, report to the Chief Executive Officer of the Company and the Parent and have such customary responsibilities, duties and authority normally associated with such position and as may from time to time be assigned
to Executive by the Chief Executive Officer of the Company or the Board (as defined below). Executive shall devote substantially 

 
all of Executive’s working time and efforts to the business and affairs of the Company (which shall include service to its parents, subsidiaries and affiliates) and shall not engage in
outside business activities (including serving on outside boards or committees) without the consent of the Chief Executive Officer, provided that Executive shall be permitted to (i) manage Executive’s personal, financial and legal affairs,
(ii) participate in trade associations, (iii) serve on the board of directors of one for-profit enterprise (whether public or private), subject to the consent of the Chief Executive Officer of the
Company, such consent not to be unreasonably withheld, and (iv) serve on the board of directors of not-for-profit or
tax-exempt charitable organizations, in each case, subject to Section 5 and the Proprietary Information Agreement and provided that such activities do not interfere with Executive’s
performance of Executive’s duties and responsibilities hereunder. Executive agrees to observe and comply with the rules and policies of the Company and its affiliates as adopted from time to time, in each case as amended from time to time, as
delivered or made available to Executive (each, a “Policy”). During the Term, Executive’s primary work location shall be Wilmington, North Carolina. Executive acknowledges that he shall be required to travel on business in
connection with the performance of his duties hereunder. 
  

	2.	 Compensation and Related Matters. 

(a)     Annual Base Salary. During the Term, Executive shall receive a base salary at a rate of $495,000 per annum
(the “Annual Base Salary”), which shall be paid in accordance with the customary payroll practices of the Company. Such Annual Base Salary shall be reviewed and may be adjusted from time to time by the board of directors of the
Company or an authorized committee thereof (in any case, the “Board”), provided that the Annual Base Salary may not be decreased without Executive’s consent. 

(b)     Bonus. During the Term, Executive will be eligible to participate in an incentive program established by
the Company. For the calendar year 2018, the Company shall pay Executive a one-time, fixed cash bonus equal to $225,000 on or about the same date on which cash bonuses are paid under the Company’s Senior
Executive Incentive Compensation Plan, as amended from time to time (the “SEICP”), with respect to calendar year 2018. For subsequent calendar years during the Term, Executive’s annual bonus compensation under such incentive
program shall be targeted at 75% of the Annual Base Salary (the “Target Bonus Amount”). The Annual Bonus shall be based on the achievement of applicable Company and individual performance metrics set forth in or established under
the SEICP. The payment of any bonus under this Section 2(b) (a “Bonus”) shall be paid to Executive on or about the same date on which cash bonuses are paid under the SEICP with respect to the applicable year and subject
to Executive’s continued employment with the Company through the date of payment; provided however that if Executive’s employment shall terminate (other than as a result of the Company’s termination of Executive’s employment for
Cause pursuant to Section 3(a)(iii) or as a result of Executive’s resignation without Good Reason pursuant to Section 3(a)(vi)) on or after January 1 of an applicable year, Executive shall be entitled to receive any
earned but unpaid Bonus for the prior year pursuant to this Section 2(b) payable at the time set forth herein but in all events no later than December 31st of the year in which the Date of Termination occurs. 

(c)     Benefits. During the Term, Executive shall be eligible to participate in employee benefit plans, programs
and arrangements of the Company to the same extent as other senior-level executives (excluding aircraft use, severance benefits or the right to receive equity-based compensation), consistent with the terms thereof and as such plans, programs and
arrangements may be amended from time to time. In no event shall Executive be eligible to participate in any severance plan or program of the Company, except as set forth in Section 4 of this Agreement. The Company will provide Executive
with the relocation benefits set forth in a Relocation Agreement to be entered into by Executive and Company in substantially the form attached hereto as Exhibit B, subject to the terms and conditions thereof. 

  
 2 

 (d)     Vacation. During the Term, Executive shall be entitled to
paid personal leave in accordance with the Company’s Policies. Any vacation shall be taken at the reasonable and mutual convenience of the Company and Executive. 

(e)     Expenses. During the Term, the Company shall reimburse Executive for all reasonable travel and other
business expenses incurred by Executive in the performance of Executive’s duties to the Company in accordance with the Company’s expense reimbursement Policy. 

(f)     Key Person Insurance. At any time during the Term, the Company shall have the right to insure the life of
Executive for the Company’s sole benefit. The Company shall have the right to determine the amount of insurance and the type of policy. Executive shall reasonably cooperate with the Company in obtaining such insurance by submitting to physical
examinations, by supplying all information reasonably required by any insurance carrier, and by executing all necessary documents reasonably required by any insurance carrier, provided that any information provided to an insurance company or broker
shall not be provided to the Company without the prior written authorization of Executive. Executive shall incur no financial obligation by executing any required document, and shall have no interest in any such policy. Additionally, and
notwithstanding the preceding to the contrary, in the event the amount of insurance adversely affects the amount of life insurance Executive seeks and is qualified to obtain at any time during the Term, then the Company agrees to reduce the amount
of the insurance. 
 (g)     Sign-On Bonus. In addition to the other
compensation set forth herein, the Company will pay Executive a one-time cash sign-on bonus of $175,000, less normal withholdings, on or about July 23, 2018 in
accordance with the terms and conditions set forth in the Sign-On Bonus Agreement attached hereto as Exhibit C to be entered into by the Company and Executive. 

(h)     Stock Option Grant. On or before June 30, 2018, Executive will be eligible to receive a non-qualified stock option to purchase a number of shares of non-voting common stock of the Parent having a strike value equal to $12,000,000 (the “Option
Grant”). The number of options intended to be granted to Executive pursuant to the Option Grant will equal the strike value divided by the fair market value of the Parent’s non-voting common
stock on the date the non-qualified stock options are approved by the compensation committee of the board of directors of the Parent. It is intended that the Option Grant will consist of the following types
and strike values: $5,000,000 time options, $5,000,000 performance options and $2,000,000 realization options. Once this Option Grant has been approved by the Compensation Committee of the Board, the Option Grant will be granted pursuant to the form
of the Stock Option Agreement attached hereto as Exhibit D and the side letter attached hereto as Exhibit E. The Option Grant will also be subject to the terms and conditions of the Parent’s 2017 Equity Incentive
Plan, as may be amended or supplemented from time to time. 
  

	3.	 Termination. 

Executive’s employment hereunder may be terminated by the Company or Executive, as applicable, without any breach of this Agreement under
the following circumstances: 
 (a)     Circumstances. 

(i)     Death. Executive’s employment hereunder shall terminate upon Executive’s death.

 (ii)     Disability. If Executive has incurred a Disability, as defined below, the Company may
terminate Executive’s employment. 

  
 3 

 (iii)    Termination for Cause. The Company may
terminate Executive’s employment for Cause, as defined below. 
 (iv)    Termination without
Cause. The Company may terminate Executive’s employment without Cause, which shall include a termination of Executive’s employment as a result of the Company not renewing the Term pursuant to Section 1. 

(v)    Resignation from the Company for Good Reason. Executive may resign Executive’s
employment with the Company for Good Reason, as defined below. 
 (vi)    Resignation from the Company
without Good Reason. Executive may resign Executive’s employment with the Company for any reason other than Good Reason or for no reason, which shall include a termination of Executive as a result of Executive not renewing the Term pursuant
to Section 1. 
 (b)     Notice of Termination. Any termination of Executive’s employment by the
Company or by Executive under this Section 3 (other than termination pursuant to paragraph (a)(i)) shall be communicated by a written notice to the other party hereto (i) indicating the specific termination provision in this
Agreement relied upon, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated, if applicable, and (iii) specifying a
Date of Termination which, if submitted by Executive, shall, except in the event of Executive’s resignation from the Company for Good Reason pursuant to Section 3(a)(v), be at least sixty (60) days following the date of such
notice (a “Notice of Termination”); provided, however, that in the event that Executive delivers a Notice of Termination to the Company, the Company may, in its sole discretion, change the Date of Termination to any date that
occurs following the date of Company’s receipt of such Notice of Termination and is prior to the date specified in such Notice of Termination. A Notice of Termination submitted by the Company may provide for a Date of Termination on the date
Executive receives the Notice of Termination, or any date thereafter elected by the Company in its sole discretion. The failure by the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause
shall not waive any right of the Company hereunder or preclude the Company from asserting such fact or circumstance in enforcing the Company’s rights hereunder. 

(c)     Company Obligations upon Termination. Upon termination of Executive’s employment pursuant to any of
the circumstances listed in Section 3(a), Executive (or Executive’s estate) shall be entitled to receive the sum of: (i) the portion of Executive’s Annual Base Salary earned through the Date of Termination but not yet paid
to Executive; (ii) any expenses owed to Executive pursuant to the last sentence of Section 2(c) or Section 2(e); and (iii) any amount accrued and arising from Executive’s participation in, or benefits accrued
under any employee benefit plans, programs or arrangements, which amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs or arrangements (collectively, the “Company
Arrangements”). Except as otherwise expressly required by law (e.g., COBRA) or as specifically provided herein, all of Executive’s rights to salary, severance, benefits, bonuses and other compensatory amounts hereunder (if any) shall
cease upon the termination of Executive’s employment hereunder. In the event that Executive’s employment is terminated by the Company for any reason, Executive’s sole and exclusive remedy shall be to receive the severance payments and
benefits described in Section 2(b), this Section 3(c) or Section 4, as applicable. For the avoidance of doubt, Executive’s Option Grant and any other equity held by him or any equity grants which remain
outstanding shall be governed by the applicable documentation and not the provisions of this Section 3. 

  
 4 

 (d)     Deemed Resignation. Upon termination of Executive’s
employment for any reason, Executive shall be deemed to have resigned from all offices and directorships, if any, then held with the Company or any of its parents, subsidiaries or affiliates. 

 

	4.	 Severance Payments. 

(a)     Termination for Cause, Resignation from the Company Without Good Reason or Termination Upon Death or
Disability. If Executive’s employment shall terminate as a result of Executive’s death pursuant to Section 3(a)(i) or Disability pursuant to Section 3(a)(ii), pursuant to Section 3(a)(iii) for Cause
or pursuant to Section 3(a)(vi) due to Executive’s resignation from the Company without Good Reason, then Executive shall not be entitled to any severance payments or benefits, except as provided in either Section 2(b)
and/or Section 3(c). 
 (b)     Termination without Cause or Resignation from the Company for Good
Reason. 
 (i)     If Executive’s employment shall terminate without Cause pursuant to
Section 3(a)(iv) or pursuant to Section 3(a)(v) due to Executive’s resignation for Good Reason, then, subject to Executive signing on or after the date of Executive’s Separation from Service (as defined below) and
before the 21st day following Executive’s Separation from Service, and not revoking, a release of claims substantially in the form attached as Exhibit F to this Agreement (the “Release”), and Executive’s
continued compliance with Section 5 and the Proprietary Information Agreement, Executive shall receive, in addition to payments and benefits set forth in Section 2(b) and Section 3(c), the following: 

(A)     an amount in cash equal to (x) 1.5 times the Annual Base Salary of Executive as of the Date of
Termination, payable in the form of salary continuation in regular installments over the eighteen-month period following the date of Executive’s Separation from Service (the “Severance Period”) in accordance with the
Company’s normal payroll practices and (y) a pro-rated amount of the Target Bonus Amount for the year of termination based on the number of days Executive was employed during such year (or if such
termination occurs in 2018, $225,000), payable in lump sum within 30 days following the Date of Termination; and 

(B)     payment in an amount equal to the amount of the premiums Executive would be required to pay to
continue Executive’s and Executive’s covered dependents’ medical, dental and vision coverage in effect on the Date of Termination under the Company’s group healthcare plans pursuant to the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”), which amount shall be based on the premium for the first month of COBRA coverage and shall be paid on the Company’s first regular pay date of each calendar month during the
period commencing on Executive’s Separation from Service and ending upon the earliest of (Y) the last day of the Severance Period or (Z) the date Executive becomes eligible to receive healthcare coverage from a subsequent employer.

 (ii)     Executive shall not be obligated to seek other employment or take any other action by way of
mitigation of the amounts payable to Executive under this Section 4(b), and such amounts shall not be reduced whether or not Executive obtains other employment. In addition, the amounts under this Section 4(b) shall not be subject
to forfeiture for any alleged breach of Section 5 of this Agreement and the Proprietary Information Agreement unless the Company provides Executive with written notice of the events or omissions giving rise to such forfeiture and, if
curable Executive fails to cure such event or omission within ten (10) business days after receipt of such notice and in the case of any confidentiality obligation or the Proprietary Information Agreement the breach is material.

  
 5 

 (c)     Survival. Notwithstanding anything to the contrary in
this Agreement, the provisions of Sections 2(b), 3(c), 4, 5 through 7, and 9 will survive the termination of Executive’s employment and the expiration or termination of the Term. 

 

	5.	 Competition. 

Executive acknowledges that the Company has provided and, during the Term, the Company from time to time will continue to provide Executive
with access to its confidential information. Ancillary to the rights provided to Executive as set forth in this Agreement and the Company’s provision of confidential information, and Executive’s agreements regarding the use of same, in
order to protect the value of any confidential information, the Company and Executive agree to the following provisions against unfair competition, which Executive acknowledges represent a fair balance of the Company’s rights to protect its
business and Executive’s right to pursue employment: 
 (a)     Executive shall not, at any time during the
Restricted Period (as defined below), directly or indirectly engage in, have any equity interest in, interview for a potential employment or consulting relationship with or manage, provide services to or operate any person, firm, corporation,
partnership or business (whether as director, officer, employee, agent, representative, partner, security holder, consultant or otherwise) that engages in any business which competes with any portion of the Business (as defined below) of the Company
anywhere in the world. Nothing in this Section 5(a) shall prohibit Executive from working for a pharmaceutical, biotechnology or medical device organization that is not a clinical research organization or being a passive owner of not
more than 2% of the outstanding voting securities of an entity that is publicly traded, so long as Executive has no active participation in the business of such entity. 

(b)     Executive shall not, at any time during the Restricted Period, directly or indirectly, recruit or otherwise
solicit or induce any employee, customer, subscriber or supplier of the Company to (i) terminate its employment or arrangement with the Company, or (ii) to otherwise change its relationship with the Company. Executive shall not, at any
time during the Restricted Period, directly or indirectly, either for Executive or for any other person or entity, (x) solicit any employee of the Company to terminate his or her employment with the Company, (y) employ any such individual
during his or her employment with the Company and for a period of twelve months after such individual terminates his or her employment with the Company or (z) solicit any vendor or business affiliate of the Company to cease to do business with
the Company. 
 (c)     In the event the terms of this Section 5 shall be determined by any court of
competent jurisdiction to be unenforceable by reason of its extending for too great a period of time or over too great a geographical area or by reason of its being too extensive in any other respect, it will be interpreted to extend only over the
maximum period of time for which it may be enforceable, over the maximum geographical area as to which it may be enforceable, or to the maximum extent in all other respects as to which it may be enforceable, all as determined by such court in such
action. 
 (d)     As used in this Section 5, (i) the term “Company” shall include the
Company and its direct and indirect parents and subsidiaries; (ii) the term “Business” shall mean the business of the Company and shall include providing drug discovery, drug development or laboratory services to
pharmaceutical, biotechnology, medical device, government and academic organizations, as such business may be conducted or contemplated during the Term and (iii) the term “Restricted Period” shall mean the period beginning on
the Effective Date and ending on the date that is 18 months following the Date of Termination. 

  
 6 

 (e)     Each of the Parties (which, in the case of the Company, shall
mean its officers and the members of the Board) agrees, during the Term and following the Date of Termination, to refrain from Disparaging (as defined below) the other Party and its affiliates, including, in the case of the Company, any of its
services, technologies or practices, or any of its directors, officers, agents, representatives or stockholders, either orally or in writing. Nothing in this paragraph shall preclude any Party from making truthful statements that are reasonably
necessary to comply with applicable law, regulation or legal process, or to defend or enforce a Party’s rights under this Agreement. For purposes of this Agreement, “Disparaging” means making remarks, comments or statements,
whether written or oral, that impugn the character, integrity, reputation or abilities of the Person being disparaged. 

(f)     Executive represents that Executive’s employment by the Company does not and will not breach any agreement
with any former employer, including any non-compete agreement or any agreement to keep in confidence or refrain from using information acquired by Executive prior to Executive’s employment by the Company.
During Executive’s employment by the Company, Executive agrees that Executive will not violate any non-solicitation agreements Executive entered into with any former employer or improperly make use of, or
disclose, any information or trade secrets of any former employer or other third party, nor will Executive bring onto the premises of the Company or use any unpublished documents or any property belonging to any former employer or other third party,
in violation of any lawful agreements with that former employer or third party. 
  

	6.	 Injunctive Relief. 

It is recognized and acknowledged by Executive that a breach of any covenant contained in Section 5 will cause irreparable damage
to Company and its goodwill, the exact amount of which will be difficult or impossible to ascertain, and that the remedies at law for any such breach will be inadequate. Accordingly, Executive agrees that in the event of a breach of any covenant
contained in Section 5, in addition to any other remedy which may be available at law or in equity, the Company will be entitled to specific performance and injunctive relief. 

 

	7.	 Assignment and Successors. 

The Company may assign its rights and obligations under this Agreement to any of its affiliates provided that the Company remains secondarily
liable hereunder or to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise), and may assign or encumber this Agreement and its rights hereunder as security for indebtedness of the Company
and its affiliates. This Agreement shall be binding upon and inure to the benefit of the Company, Executive and their respective successors, assigns, personnel and legal representatives, executors, administrators, heirs, distributees, devisees, and
legatees, as applicable. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only by will or operation of law. Notwithstanding
the foregoing, Executive shall be entitled, to the extent permitted under applicable law and applicable Company Arrangements, to select and change a beneficiary or beneficiaries to receive compensation or severance hereunder following
Executive’s death by giving written notice thereof to the Company (provided if no such notice is given such amounts shall be payable to Executive’s estate). 

  
 7 

	8.	 Certain Definitions. 

(a)     Cause. The Company shall have “Cause” to terminate Executive’s employment hereunder upon:

 (i)     Executive’s willful failure or willful refusal to (x) substantially perform
Executive’s duties with the Company (other than any such failure resulting from Executive’s Disability) or (y) comply with, in any material respect, any of the Company’s material Policies; 

(ii)     Executive’s material breach of Section 5 of this Agreement, the Proprietary
Information Agreement or any other material written agreement between Executive and the Company or any of its affiliates with respect to any restrictive covenants in such agreements; 

(iii)     Executive’s conviction, plea of no contest, plea of nolo contendere, or imposition of
unadjudicated probation (A) for any felony or (B) for any crime (other than a traffic violation) involving moral turpitude that is materially harmful to the business or reputation of the Company or any of its affiliates; 

(iv)     Executive’s unlawful use (including being under the influence) or possession of illegal drugs
on the Company’s (or any of its affiliate’s) premises or while performing Executive’s duties and responsibilities under this Agreement; or 

(v)     Executive’s commission of an act of fraud, embezzlement, misappropriation or willful
misconduct against the Company or any of its affiliates. 
 Prior to Executive’s termination for Cause, the Company must provide
written notice to Executive describing the act or omission that constitutes Cause and, in respect of circumstances capable of cure, such circumstances must remain uncured for thirty (30) days following the date of such written notice. 

(b)     Date of Termination. “Date of Termination” shall mean (i) if Executive’s
employment is terminated by Executive’s death, the date of Executive’s death; (ii) if Executive’s employment is terminated pursuant to Section 3(a)(ii) – (vi) (other than a notice of non-renewal of the Term by the Company) the earlier of the date indicated in the Notice of Termination or the date specified by the Company pursuant to Section 3(b); or (iii) if the termination of
Executive’s employment is pursuant to a notice of non-renewal of the Term provided by the Company, the last day of the applicable Term. 

(c)     Disability. “Disability” shall mean Executive’s inability to perform, with or without
reasonable accommodation, the essential functions of Executive’s position hereunder for a total of 90 days during any 12 month period as a result of incapacity due to mental or physical illness as determined in good faith by the Board or the
Chief Executive Officer of the Company. 
 (d)     Good Reason. “Good Reason” means the occurrence of
any of the following without Executive’s consent: 
 (i)     a reduction in Executive’s
then-current Annual Base Salary or Target Bonus Amount, 
 (ii)     the relocation of Executive’s
primary work location to a location that is more than twenty-five (25) miles from Executive’s then-current primary work location, 

  
 8 

 (iii)     a material adverse reduction in
Executive’s duties or responsibilities as in effect on the date hereof, including removal of Executive as Chief Financial Officer of the Company or the Parent, or 

(iv)     a material breach by the Company or any of its affiliates of this Agreement or any other material
written agreements to which Executive is a party, including the failure of Executive to report directly to the Company’s and the Parent’s Chief Executive Officer. 

Notwithstanding the foregoing, no Good Reason will have occurred unless (A) Executive shall have delivered to the Company written notice
of Executive’s objection to any event set forth in clause (i)–(iv) of this Section 8(d) within ninety (90) days following the later of Executive becoming aware of such event or its occurrence, (B) such event is
not corrected, in all material respects, by the Company within thirty (30) days following the Company’s receipt of such notice and (C) Executive resigns Executive’s employment with the Company not more than thirty (30) days
following the expiration of the 30-day correction period described in the foregoing clause (B). 

(e)     Person. “Person” shall mean any individual, firm, corporation, partnership, limited liability
company, incorporated or unincorporated association, joint venture, joint stock company, trust, governmental authority or other entity of any kind. 
  

	9.	 Miscellaneous Provisions. 

(a)     Governing Law. This Agreement shall be governed, construed, interpreted and enforced in accordance with its
express terms, and otherwise in accordance with the substantive laws of the State of North Carolina without reference to the principles of conflicts of law of the State of North Carolina or any other jurisdiction, and where applicable, the laws of
the United States.  
 (b)     Validity. The invalidity or unenforceability of any provision or provisions
of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.  

(c)     Notices. Any notice, request, claim, demand, document and other communication hereunder to any Party shall
be effective upon receipt (or refusal of receipt) and shall be in writing and delivered personally or sent by facsimile or certified or registered mail, postage prepaid, as follows: 

 

	 	(i)	 If to the Company: 

Pharmaceutical Product Development, LLC 

929 North Front Street 

Wilmington, NC 28401 

Attention: General Counsel 

Facsimile: [                ] 

and a copy (which shall not constitute notice) to: 

The Carlyle Group 
 520 Madison
Avenue 
 New York, New York 10022 

Attention: Stephen Wise 

Facsimile: [                ] 

  
 9 

 and 

Hellman & Friedman LLC 

One Maritime Plaza, 12th Fl. 

San Francisco, California 94111 

Attention: Arrie Park 

Facsimile: [                ] 

and 
 Simpson
Thacher & Bartlett LLP 
 425 Lexington Avenue 

New York, New York 10017 

Attention: David E. Rubinsky 

Facsimile: [                ] 

(ii)     If to Executive, at the last address that the Company has in its personnel records for Executive,
or 
 (iii)     At any other address as any Party shall have specified by notice in writing to the other
Party. 
 (d)     Counterparts. This Agreement may be executed in several counterparts, each of which shall be
deemed to be an original, but all of which together will constitute one and the same Agreement. Signatures delivered by facsimile shall be deemed effective for all purposes. 

(e)     Entire Agreement. The terms of this Agreement and its Exhibits are intended by the Parties to be the final
expression of their agreement with respect to the employment of Executive by the Company and supersede all prior understandings and agreements, whether written or oral, including without limitation the Offer Letter; provided, however, (i) the
conditions precedent to the employment of Executive set forth in the Offer Letter relating to passing a pre-employment drug screen, a satisfactory background check and proof of identity and the right to work
in the United States are not superseded, but shall remain in full force and effect, and (ii) in the event such conditions precedent are not satisfied, this Agreement shall be deemed terminated on the date specified by the Company in written
notice thereof to Executive and the Company shall have no liability or obligation to Executive hereunder, including without limitation Sections 2 and 4 hereof. The Company agrees to provide Executive with prompt written notice once he has satisfied
any of these pre-conditions and if the Company fails to inform Executive in writing by June 30, 2018 that he has failed to satisfy any of these pre-conditions, he
will be deemed to have satisfied them as of June 30, 2018. The Parties further intend that this Agreement (including its Exhibits) shall constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever
may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement. 

(f)     Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in
writing, signed by Executive and a duly authorized officer of Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company may waive compliance by the other Party with any specifically identified
provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent failure. No
failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity. 

  
 10 

 (g)    No Inconsistent Actions. The Parties hereto shall not
voluntarily undertake or fail to undertake any action or course of action inconsistent with the provisions or essential intent of this Agreement. Furthermore, it is the intent of the Parties hereto to act in a fair and reasonable manner with respect
to the interpretation and application of the provisions of this Agreement. 
 (h)    Construction. This Agreement
shall be deemed drafted equally by both the Parties. Its language shall be construed as a whole and according to its fair meaning. Any presumption or principle that the language is to be construed against any Party shall not apply. The headings in
this Agreement are only for convenience and are not intended to affect construction or interpretation. Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement, unless the context clearly indicates to
the contrary. Also, unless the context clearly indicates to the contrary, (a) the plural includes the singular and the singular includes the plural; (b) “and” and “or” are each used both conjunctively and disjunctively; (c)
“any,” “all,” “each,” or “every” means “any and all,” and “each and every”; (d) “includes” and “including” are each “without limitation”; (e)
“herein,” “hereof,” “hereunder” and other similar compounds of the word “here” refer to the entire Agreement and not to any particular paragraph, subparagraph, section or subsection; and (f) all pronouns
and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the entities or persons referred to may require. 

(i)    Arbitration. Any controversy, claim or dispute arising out of or relating to this Agreement, shall be
settled solely and exclusively by a binding arbitration process administered by the American Arbitration Association (the “AAA”) in Wilmington, North Carolina. Such arbitration shall be conducted in accordance with the then-existing
rules of Practice and Procedure, with the following exceptions if in conflict: (a) one arbitrator who is a retired judge shall be chosen by AAA; (b) each Party to the arbitration will pay one-half of
the expenses and fees of the arbitrator, together with other expenses of the arbitration incurred or approved by the arbitrator, except that the Company shall pay all of such fees and expenses if Executive is the prevailing party in the arbitration;
and (c) arbitration may proceed in the absence of any Party if written notice (pursuant to the AAA rules and regulations) of the proceedings has been given to such Party. Each Party shall bear its own attorneys’ fees and expenses. The
Parties agree to abide by all decisions and awards rendered in such proceedings. Such decisions and awards rendered by the arbitrator shall be final and conclusive. All such controversies, claims or disputes shall be settled in this manner in lieu
of any action at law or equity; provided, however, that nothing in this subsection shall be construed as precluding the bringing an action for injunctive relief or specific performance as provided in this Agreement. This dispute
resolution process and any arbitration hereunder shall be confidential and neither any Party nor the neutral arbitrator shall disclose the existence, contents or results of such process without the prior written consent of all Parties, except where
necessary or compelled in a Court to enforce this arbitration provision or an Award from such arbitration or otherwise in a legal proceeding. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or
dispute over intellectual property rights by Court action instead of arbitration. 
 (j)    Enforcement. If any
provision of this Agreement is held to be illegal, invalid or unenforceable under present or future laws effective during the term of this Agreement, such provision shall be fully severable; this Agreement shall be construed and enforced as if such
illegal, invalid or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable
provision or by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid or unenforceable provision there shall be added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid or
unenforceable provision as may be possible and be legal, valid and enforceable. 

  
 11 

 (k)    Withholding. The Company shall be entitled to withhold
from any amounts payable under this Agreement any federal, state, local or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on an opinion of counsel if any questions as to
the amount or requirement of withholding shall arise. 
 (l)    Section 409A. 

(i)    General. The intent of the Parties is that the payments and benefits under this Agreement
comply with or be exempt from Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively, “Section 409A”) and, accordingly, to the maximum extent
permitted, this Agreement shall be interpreted to be in compliance therewith. 
 (ii)    Separation
from Service. Notwithstanding anything in this Agreement to the contrary, any compensation or benefits payable under this Agreement that is considered nonqualified deferred compensation under Section 409A and is designated under this
Agreement as payable upon Executive’s termination of employment shall be payable only upon Executive’s “separation from service” with the Company within the meaning of Section 409A (a “Separation from
Service”) and, except as provided below, any such compensation or benefits shall not be paid, or, in the case of installments, shall not commence payment, until the thirtieth (30th) day following Executive’s Separation from Service.
Any installment payments that would have been made to Executive during the thirty (30) day period immediately following Executive’s Separation from Service but for the preceding sentence shall be paid to Executive on the thirtieth (30th)
day following Executive’s Separation from Service and the remaining payments shall be made as provided in this Agreement. 

(iii)    Specified Employee. Notwithstanding anything in this Agreement to the contrary, if
Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A, to the extent delayed commencement of any portion of the benefits to which Executive
is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) the expiration of the six-month period measured from the date of Executive’s Separation from Service with the Company or (ii) the date of Executive’s death. Upon the first business day following the expiration of the
applicable Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive’s estate or beneficiaries), and any remaining payments due to Executive under this Agreement
shall be paid as otherwise provided herein. 
 (iv)    Expense Reimbursements. To the extent that
any reimbursements under this Agreement or its Exhibits are subject to Section 409A, any such reimbursements payable to Executive shall be paid to Executive no later than December 31 of the year following the year in which the expense was
incurred; provided that Executive submits Executive’s reimbursement request promptly following the date the expense is incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any
subsequent year, other than medical expenses referred to in Section 105(b) of the Code, and Executive’s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit. 

(v)    Installments. Executive’s right to receive any installment payments under this
Agreement, including without limitation any continuation salary payments that are payable on 

  
 12 

 
Company payroll dates, shall be treated as a right to receive a series of separate payments and, accordingly, each such installment payment shall at all times be considered a separate and
distinct payment as permitted under Section 409A. Except as otherwise permitted under Section 409A, no payment hereunder shall be accelerated or deferred unless such acceleration or deferral would not result in additional tax or interest
pursuant to Section 409A. 
 (vi)    Company Discretion. Whenever a payment under this
Agreement specifies a payment period with reference to a number of days (e.g., “payment shall be made within thirty (30) days following the date of termination”), the actual date of payment within the specified period shall be within
the Company’s sole discretion and if such payment period spans two calendar years, shall be paid in the portion of the payment period that falls in the second calendar year. 

(m)    Indemnification; Insurance. During the Term and thereafter, the Company and the Parent shall indemnify and
hold Executive (including Executive’s heirs, personal representatives, executors and administrators) harmless, to the maximum extent permitted by law, against any and all damages, costs, liabilities, and losses as a result of any third party
(excluding the Company, the Parent and any of their affiliates) claim or proceeding, or any threatened third-party (excluding the Company, the Parent and any of their affiliates) claim or proceeding, against Executive that arises out of or relates
to Executive by reason of Executive having been or having provided service as an officer, director or employee, as the case may be, of the Company and/or the Parent, or Executive’s service in any such capacity or similar capacity with an
affiliate of the Company or the Parent or other entity at the request of the Company or the Parent (in all cases, subject to limitations on bad acts and any other limitations under applicable law which preclude such indemnification and excluding any
and all damages, costs, liabilities and losses related to Executive’s remuneration). The Company shall advance to Executive all costs and expenses incurred by him in connection with any proceeding covered by this provision within twenty
calendar days after receipt by the Company of a written request for such advance. Such request shall include an undertaking by Executive to repay the amount of such advance if it is ultimately determined by a court of competent jurisdiction that he
is not entitled to be indemnified against any such costs and/or expenses. The Company shall maintain or cause to be maintained for Executive Directors’ and Officers’ insurance to the same extent provided to active officers of the Company
and/or the Parent in respect of those liabilities which Executive may incur as a director or officer of the Company, the Parent or any of its affiliates for which such insurance is normally available. Executive’s rights under this
Section 9(m) shall be in addition to, and not in lieu of, any other rights he has to be indemnified, advanced expenses and/or covered under directors’ and officers’ liability insurance policies under any other agreements or policies
of the Company, the Parent or any of their affiliates, including pursuant to the Parent’s Stockholders Agreement. 

(n)    Parent Guarantee. In the event that the Company shall fail to satisfy any matured payment obligation to
Executive under this Agreement, Parent agrees to satisfy such payment obligation, subject to all of the terms and conditions of this Agreement and applicable law. 
  

	10.	 Employee Acknowledgement. 

Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance
upon any representations or promises made by the Company other than those contained in writing herein, and has entered into this Agreement freely based on Executive’s own judgment. 

[Signature Page Follows] 

  
 13 

 IN WITNESS WHEREOF, the Parties have executed this Agreement on the date and year first
above written. 
  

					
	COMPANY
		
	By:	 	 /s/ B. Judd Hartman

		 	Name:	 	B. Judd Hartman
		 	Title:	 	General Counsel
	
	EXECUTIVE
		
	By:	 	 /s/ Christopher G. Scully

	
	Solely with respect to Sections 1(c), 2(h), 9(m) and 9(n):
	
	PARENT
		
	By:	 	 /s/ B. Judd Hartman

		 	Name:	 	B. Judd Hartman
		 	Title:	 	General Counsel

 Signature Page to Employment Agreement (C. Scully)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]